Publicaciones en colaboración con investigadores/as de University of Padua (26)

2022

  1. Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma

    European Journal of Cancer, Vol. 162, pp. 221-236

  2. International Multicenter Study of Clinical Outcomes of Sinonasal Melanoma Shows Survival Benefit for Patients Treated with Immune Checkpoint Inhibitors and Potential Improvements to the Current TNM Staging System

    Journal of Neurological Surgery, Part B: Skull Base, Vol. 84, Núm. 4, pp. 307-319

2017

  1. A BARF1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumors

    OncoImmunology, Vol. 6, Núm. 4

  2. Fighting viral infections and virus-driven tumors with cytotoxic CD4+ T cells

    Frontiers in Immunology, Vol. 8, Núm. FEB

2016

  1. A site-selective hyaluronan-interferonα2a conjugate for the treatment of ovarian cancer

    Journal of Controlled Release, Vol. 236, pp. 79-89

  2. Characterization of endolymphatic sac tumors and von Hippel-Lindau disease in the International Endolymphatic Sac Tumor Registry

    Head and Neck, Vol. 38, pp. E673-E679

  3. Reverse immunoediting: When immunity is edited by antigen

    Immunology Letters, Vol. 175, pp. 16-20

2015

  1. Drug conjugation to hyaluronan widens therapeutic indications for ovarian cancer

    Oncoscience, Vol. 2, Núm. 4, pp. 373-381

  2. Inventory of current EU paediatric vision and hearing screening programmes

    Journal of Medical Screening, Vol. 22, Núm. 2, pp. 55-64

2014

  1. Functional avidity-driven activation-induced cell death shapes CTL immunodominance

    Journal of Immunology, Vol. 193, Núm. 9, pp. 4704-4711

  2. PSMA-Specific CAR-Engineered T Cells Eradicate Disseminated Prostate Cancer in Preclinical Models

    PLoS ONE, Vol. 9, Núm. 10

  3. Peritoneal tumor carcinomatosis: Pharmacological targeting with hyaluronan-based bioconjugates overcomes therapeutic indications of current drugs

    PLoS ONE, Vol. 9, Núm. 11

2013

  1. Survivin expression and prognostic significance in pediatric malignant peripheral nerve sheath tumors (MPNST)

    PLoS ONE, Vol. 8, Núm. 11

2012

  1. Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for epstein-barr-virus-driven disorders

    Clinical and Developmental Immunology, Vol. 2012

  2. IGKV3 proteins as candidate "off-the-shelf" vaccines for kappa-light chain-restricted B-cell non-Hodgkin lymphomas

    Clinical Cancer Research, Vol. 18, Núm. 15, pp. 4080-4091

  3. MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma

    Clinical Cancer Research, Vol. 18, Núm. 10, pp. 2828-2837

2011

  1. Differential down-modulation of HLA class i and II molecule expression on human tumor cell lines upon in vivo transfer

    Cancer Immunology, Immunotherapy, Vol. 60, Núm. 11, pp. 1639-1645

  2. Immunotherapy for EBV-associated malignancies

    International Journal of Hematology, Vol. 93, Núm. 3, pp. 281-293

2010

  1. Impact of γ-chain cytokines on EBV-specific T cell cultures

    Journal of Translational Medicine, Vol. 8

  2. Role of CD4 cytotoxic T lymphocytes in the control of viral diseases and cancer

    International Reviews of Immunology, Vol. 29, Núm. 4, pp. 371-402